Paper Details

  1. Home
  2. Paper Details

Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.

Author: BarbaranoLuciana, CafroAnna Maria, CaravitaTommaso, CorsoAlessandro, GayFrancesca, LazzarinoMario, MangiacavalliSilvia, MorraEnrica, PalumboAntonio, PetrucciMaria Teresa, VarettoniMarzia, ZappasodiPatrizia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Thalidomide has been used in the treatment of multiple myeloma (MM). This study assessed the long-term efficacy and toxicity of thalidomide, either alone or in combination with steroids, in patients with MM. The study found that thalidomide produced a high response rate with varying outcomes based on response quality and duration.
Paper Details　
Original Abstract of the Article :
A total of 303 MM patients were retrospectively reviewed to evaluate long-term efficacy and toxicity of thalidomide alone or in combination with steroids. Overall response rate was 57% (CR/VGPR 12%). Median TTP, PFS and OS were 13.4 months, 20.6 months, and 26.2 months, respectively. PFS and OS were...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.leukres.2009.03.015

データ提供：米国国立医学図書館（NLM）

Thalidomide for Relapsed and Refractory Multiple Myeloma: A Journey Through the Desert of Treatment

This study delves into the complex world of multiple myeloma (MM), a challenging disease that can be like navigating a vast and treacherous desert. The researchers are exploring the use of thalidomide, a medication that has shown promise in treating relapsed and refractory MM. This research is like seeking a hidden oasis of hope in the desert, offering potential relief for patients facing a difficult diagnosis.

Finding Hope in the Desert

The study found that thalidomide, used alone or in combination with steroids, produced a high response rate in patients with relapsed or refractory MM. This is like discovering a source of water in a dry desert, offering a lifeline of hope for patients facing difficult challenges. The researchers noted that patients who achieved a complete or very good partial response to thalidomide had a significantly longer progression-free survival and overall survival.

Navigating the Side Effects

This study highlights the potential benefits of thalidomide for patients with relapsed or refractory MM, but it also acknowledges the need to manage potential side effects. This is like navigating a desert with hidden dangers, requiring careful attention to potential hazards and a willingness to adapt strategies as needed. The study suggests that while thalidomide can offer hope, it's crucial to carefully monitor patients for side effects and adjust treatment plans accordingly.

Dr.Camel's Conclusion

This study offers a beacon of hope for patients with relapsed or refractory multiple myeloma, showcasing the potential benefits of thalidomide therapy. It's like finding a hidden oasis in the desert, offering a source of strength and resilience to those facing a difficult diagnosis. However, it's important to remember that even in the most promising of treatments, there are potential challenges and side effects that require careful monitoring and management.
Date :
  1. Date Completed 2009-07-15
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

19375164

DOI: Digital Object Identifier

10.1016/j.leukres.2009.03.015

Related Literature

Article Analysis
・Side Effects of thalidomide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.